Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Partici

Indication
Neutropenia

Other upcoming events for XFOR

Phase 3 ReadoutPhase 3 Topline: A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positiv
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety
Patent ExpiryPatent/Exclusivity Expiry: NINLARO

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Partici — XFOR Phase 3 Readout | BioSniper